We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Hodgkin's Disease Patients Sought for Trial of MoAb

Sep 1, 1995
Volume: 
4
Issue: 
9
  • Hodgkin Lymphoma

BOSTON, Mass--Researchers at New England Deaconess Hospital are
seeking Hodgkin's disease patients for a federally funded phase
Ib/II trial of a humanized monoclonal antibody (MoAb) against
interleukin-2 receptor (Tac).

The rationale for the study stems from the observation that all
Reed-Sternberg cells are Tac-positive. The monoclonal antibody
under study is the humanized version of the murine anti-Tac antibody
that generated a 33% response rate (partial response plus complete
response) in 19 patients with ATL (adult T-cell leukemia/lymphoma)
at the National Cancer Institute (see figure).

The new molecule is 92% human in origin, resulting in increased
effectiveness in cytotoxicity assays and reduced immunogenicity
during therapy (Queen et al: Proc Natl Acad Sci USA 86:10029,
1989; Junghans et al: Cancer Research 50:1495, 1990).

Eligibility requirements for the protocol (92-0205-34) include
measurable disease, failed first- and second-line treatments,
and PS 0-2. Patients must be able to remain in Boston for the
first study month of this outpatient trial. Treatment response
at 1 month is required to continue participation.

For more information, contact Richard P. Junghans, PhD, MD, at
New England Deaconess Hospital; telephone:

617-632-0943; fax: 617-632-0998.

Related Articles

  • Brentuximab Vedotin Approved for Classical HL
  • FDA Approval of Brentuximab Vedotin With Chemo Offers New Hope for Stage III/IV Hodgkin Lymphoma
  • Anti-PD-1 Therapy May Benefit Patients with Hematologic Malignancies
  • Engineered Tumor-Specific T Cells May Help Relapsed Hodgkin Lymphoma Patients
  • Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.